Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types by Vivek Subbiah, Samuel J Klempner, Neeraj Agarwal, David P Carbone, Amit Mahipal, Shilpa Gupta, David Fabrizio, Jeffrey S Ross, Gerald Li, David R Gandara, Miles C Andrews, Jonathan W Riess, Ramez N Eskander, Ryon P Graf, Geoffrey R Oxnard, Sarah Sammons, Jeremy Snider, Lilia Bouzit, Cheryl Cho-Phan, Megan Price, Julia C F Quintanilha, Richard Sheng Poe Huang

“…Exploratory assessments of patients receiving ICI+chemotherapy (n=4369) observed more favorable rwOS only in TMB≥20.Conclusions Across >8000 patients treated with single-agent ICI, and within individual cancer types with sufficient power, elevated TMB based on the FDA-approved CDx was associated with more favorable rwOS compared with similar patients with lower TMB levels. …”
Get full text

Diabetes Mellitus, Extreme Insulin Resistance, and Hypothalamic-Pituitary Langerhans Cells Histiocytosis by Mathilde Sollier, Marine Halbron, Jean Donadieu, Ahmed Idbaih, Fleur Cohen Aubart, Corinne Vigouroux, Martine Auclair, Olivier Bourron, Marie Bastin, Géraldine Béra, Philippe Touraine, Jacques Young, Héléna Mosbah, Agnès Hartemann, Fabrizio Andreelli, Chloé Amouyal

“…Each episode of hyperglycemia appeared to be correlated with tumoral activity and increase in serum anti-insulin receptor antibodies and appeared to be improved when the disease was controlled by chemotherapy. Conclusion. We report the first description of a hypothalamopituitary histiocytosis associated with serum anti-insulin receptor antibodies, extreme insulin resistance, and diabetes. …”
Get full text

Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13]) by A. DeMichele, A. C. Dueck, D. Hlauschek, M. Martin, H. Burstein, G. Pfeiler, N. Zdenkowski, A. Wolff, M. Bellet-Ezquerra, E. Winer, M. Balic, K. Miller, M. Colleoni, D. Lake, G. Rubovsky, D. Cameron, J. Balko, C. F. Singer, Z. Nowecki, H. Iwata, N. Wolmark, K. A. Parraga, H. Rugo, G. G. Steger, T. Traina, G. Werutsky, D. Czajkowska, O. Metzger, S. El-Abed, K. P. Theall, R. D. Lu, P. O’Brien, C. Fesl, E. Mayer, M. Gnant

“…There was no differential benefit by histologic grade, chemotherapy receipt, age, or anatomic/clinical risk. …”
Get full text

Global insights into MRSA bacteremia: a bibliometric analysis and future outlook by Jia-Yi Lin, Jia-Yi Lin, Jia-Kai Lai, Jia-Kai Lai, Jian-Yi Chen, Jian-Yi Chen, Jia-Yu Cai, Jia-Yu Cai, Zhan-Dong Yang, Zhan-Dong Yang, Liu-Qingqing Yang, Liu-Qingqing Yang, Liu-Qingqing Yang, Ze-Tao Zheng, Ze-Tao Zheng, Xu-Guang Guo, Xu-Guang Guo, Xu-Guang Guo

“…The journal with the most publications is Antimicrobial Agents and Chemotherapy, while the most cited global publication is Vincent JL’s article “Sepsis in European Intensive Care Units: Results of the SOAP Study” published in Critical Care Medicine in 2006. …”
Get full text

Hybrid azole-based conjugates as upcoming anticancer and antimicrobial agents by Luís M. T. Frija, Bruno E. C. Guerreiro, Inês C. C. Costa, Vera M. S. Isca, Lucília Saraiva, Beatriz G. Neves, Mariana Magalhães, Célia Cabral, Maria L. S. Cristiano, Patrícia Rijo

“…Conclusions: This investigation reveals the potential of distinct azole-based conjugates, in particular the tetrazole-thiadiazolyl (11) derivative, as scaffolds worth further investigations, in the frame of antimicrobial and antineoplastic chemotherapy.…”
Get full text

Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinoma by Daniel Oyon, Amaya Lopez-Pascual, Borja Castello-Uribe, Iker Uriarte, Giulia Orsi, Sofia Llorente, Jasmin Elurbide, Elena Adan-Villaescusa, Emiliana Valbuena-Goiricelaya, Ainara Irigaray-Miramon, Maria Ujue Latasa, Luz A. Martinez-Perez, Luca Reggiani Bonetti, Felipe Prosper, Mariano Ponz-Sarvise, Silvestre Vicent, Antonio Pineda-Lucena, David Ruiz-Clavijo, Bruno Sangro, Urko Aguirre Larracoechea, Tian V. Tian, Andrea Casadei-Gardini, Irene Amat, Maria Arechederra, Carmen Berasain, Jesus M. Urman, Matias A. Avila, Maite G. Fernandez-Barrena

“…CM272 also enhanced chemotherapy sensitivity and significantly inhibited tumor growth in vivo without detectable toxicity. …”
Get full text

Therapeutic benefit of the dual ALK/FAK inhibitor ESK440 in ALK-driven neuroblastoma by Seema Chugh, Jean C. Tien, Jennifer Hon, Carson Kenum, Rahul Mannan, Yunhui Cheng, Chi Chiang Li, Zainab I. Taher, Andrew D. Delekta, Pushpinder Singh Bawa, Ingrid J. Apel, Stephanie J. Miner, Xuhong Cao, Rohit Mehra, Saravana M. Dhanasekaran, Yuanyuan Qiao, Rajen Mody, Arul M. Chinnaiyan

“…Standard therapy involves highly toxic chemotherapy, surgery, radiation, and immunotherapy, and less toxic, more specific targeted therapies are urgently needed. …”
Get full text

Studying the Oncolytic Activity of <i>Streptococcus pyogenes</i> Strains Against Hepatoma, Glioma, and Pancreatic Cancer <i>In Vitro</i> and <i>In Vivo</i> by Anna N. Tsapieva, Alexander N. Chernov, Nadezhda V. Duplik, Anastasiya O. Morozova, Tatiana A. Filatenkova, Mariia A. Suvorova, Elena Egidarova, Elvira S. Galimova, Kseniya Bogatireva, Alexander N. Suvorov

“…Conventional treatment modalities, including radiation and chemotherapy, often fall short of achieving complete remission, highlighting the critical need for novel therapeutic strategies. …”
Get full text

Manganese-based immunotherapy synergized with novel supramolecular hydrogel: Advancing localized immune activation strategies in squamous cell carcinoma by Tianqing Wang, Xiaopei Hu, Xin Tian, Ying Wang, Shiyu Zhang, Silu Sun, Ning Ji, Xiaobo Luo, Qianming Chen, Xin Zeng, Hang Zhao, Jing Li

“…Head and neck squamous cell carcinoma (HNSCC) presents significant challenges for its treatment, especially for the treatment aimed at preserving maxillofacial function due to its complex anatomical structure, resistance to radiotherapy and chemotherapy, and low intertumoral immunogenicity. In this study, we introduce a novel approach employing manganese-based immunotherapy (Mn-IT) for the effective treatment of HNSCC. …”
Get full text

Racial Differences in Systemic Immune Parameters in Individuals With Lung Cancer by Mitchell S. von Itzstein, MD, Jialiang Liu, PhD, Hong Mu-Mosley, PhD, Farjana Fattah, PhD, Jason Y. Park, MD, PhD, Jeffrey A. SoRelle, MD, J. David Farrar, PhD, Mary E. Gwin, MD, David Hsiehchen, MD, Yvonne Gloria-McCutchen, Edward K. Wakeland, PhD, Suzanne Cole, MD, Sheena Bhalla, MD, Radhika Kainthla, MD, Igor Puzanov, MD, MSCI, Benjamin Switzer, DO, MHSA, MS, Gregory A. Daniels, MD, PhD, Yousef Zakharia, MD, Montaser Shaheen, MD, Jianjun Zhang, MD, PhD, Yang Xie, PhD, David E. Gerber, MD

“…Compared with White patients, Black patients had greater comorbidity (median Charlson Comorbidity Index 5 versus 3; p = 0.04) and were more likely to have received previous chemotherapy (79% versus 47%; p = 0.03). Black patients had significantly lower levels of CCL23 and CCL27 and significantly higher levels of CCL8, CXCL1, CCL26, CCL25, CCL1, IL-1b, CXCL16, and IFN-γ (all p < 0.05, false discovery rate < 0.1). …”
Get full text

Midostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemia by Romane Joudinaud, Augustin Boudry, Laurène Fenwarth, Sandrine Geffroy, Mikaël Salson, Hervé Dombret, Céline Berthon, Arnaud Pigneux, Delphine Lebon, Pierre Peterlin, Simon Bouzy, Pascale Flandrin-Gresta, Emmanuelle Tavernier, Martin Carre, Sylvie Tondeur, Lamya Haddaoui, Raphael Itzykson, Sarah Bertoli, Audrey Bidet, Eric Delabesse, Mathilde Hunault, Christian Récher, Claude Preudhomme, Nicolas Duployez, Pierre-Yves Dumas

“…Abstract: Despite the use of midostaurin (MIDO) with intensive chemotherapy (ICT) as frontline treatment for Fms-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML), complete remission rates are close to 60% to 70%, and relapses occur in >40% of cases. …”
Get full text

Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUM by Krzysztof Kalwak, Laura M. Moser, Ulrike Pötschger, Peter Bader, Katharina Kleinschmidt, Roland Meisel, Jean-Hugues Dalle, Akif Yesilipek, Adriana Balduzzi, Gergely Krivan, Evgenios Goussetis, Raquel Staciuk, Petr Sedlacek, Herbert Pichler, Peter Svec, Melissa Gabriel, Tayfun Güngör, Ernest Bilic, Jochen Buechner, Marleen Renard, Kim Vettenranta, Marianne Ifversen, Cristina Diaz-de-Heredia, Jerry Stein, Jacek Toporski, Marc Bierings, Christina Peters, Marc Ansari, Franco Locatelli

“…Abstract: The superiority of total body irradiation (TBI)–based vs chemotherapy conditioning for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in children with acute lymphoblastic leukemia (ALL) has been established in the international, prospective phase-3 FORUM study, randomizing 417 patients aged 4-18 years in complete remission (CR), who received allo-HSCT from HLA-matched sibling or unrelated donors. …”
Get full text

First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World Study by Laura Moliner, MD, Núria Zellweger, MSc, Sabine Schmid, MD, Martina Bertschinger, MD, Christine Waibel, MD, Ferdinando Cerciello, MD, PhD, Patrizia Froesch, MD, Michael Mark, MD, Adrienne Bettini, MD, Pirmin Häuptle, MD, Veronika Blum, MD, Lisa Holer, MSc, Stefanie Hayoz, PhD, Martin Früh, MD, Samreen Ahmed, FRCP, MD, MBBS, MSc, Shradha Bhagani, MD, Nicola Steele, MD, Hannah-Leigh Gray, BSc, Stephen D. Robinson, MD, Michael Davidson, MD (Res), Samantha Cox, MD, MSc, MBBCh, Taha Khalid, MD, Tom R. Geldart, MD, Luke Nolan, FRCS, PhD, Deborah C. Scott, MBChB (MRCP), Lindsay Hennah, MD, Tom Newsom-Davis, MD, PhD, Emma Rathbone, MD, PhD, Catherine Handforth, MD, Arshi Denton, MD, Shairoz Merchant, PhD, Fiona Blackhall, MD, PhD, Laetitia A. Mauti, MD, Raffaele Califano, MD, Sacha I. Rothschild, MD, PhD

“…Patients received platinum-etoposide chemotherapy in combination with immunotherapy (atezolizumab or durvalumab). …”
Get full text

Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium by Jessy Xinyi Han, Min Jung Koh, Leora Boussi, Mark Sorial, Sean M. McCabe, Luke Peng, Shambhavi Singh, Ijeoma Julie Eche-Ugwu, Judith Gabler, Maria J. Fernandez Turizo, Caroline T. MacVicar, Aditya Garg, Alexander Disciullo, Kusha Chopra, Alexandra Lenart, Emmanuel Nwodo, Jeffrey Barnes, Min Ji Koh, Eliana Miranda, Carlos Chiattone, Robert Stuver, Steven M. Horwitz, Mwanasha Merrill, Eric Jacobsen, Martina Manni, Monica Civallero, Tetiana Skrypets, Athina Lymboussaki, Massimo Federico, Yuri Kim, Jin Seok Kim, Jae Yong Cho, Thomas Eipe, Tanuja Shet, Epari Sridhar, Alok Shetty, Saswata Saha, Hasmukh Jain, Manju Sengar, Carrie Van Der Weyden, Henry Miles Prince, Ramzi Hamouche, Tinatin Murdashvili, Francine Foss, Marianna Gentilini, Beatrice Casadei, Pier Luigi Zinzani, Takeshi Okatani, Noriaki Yoshida, Sang Eun Yoon, Won-Seog Kim, Girisha Panchoo, Zainab Mohamed, Estelle Verburgh, Jackielyn Cuenca Alturas, Mubarak Al-Mansour, Josie Ford, Maria Elena Cabrera, Amy Ku, Govind Bhagat, Helen Ma, Ahmed Sawas, Khyati Maulik Kariya, Makoto Iwasaki, Forum Bhanushali, Owen A. O’Connor, Enrica Marchi, Changyu Shen, Devavrat Shah, Salvia Jain

“…Patients received either a ''novel'' single agent (SA; 35%) or cytotoxic chemotherapy (CC; 60%) for their second-line treatment. …”
Get full text

Nivolumab Effective for Gastric and Lung Cancers but Not for Multiple Myeloma in a Multiple Primary Cancer Patient by Tsukasa Yasuda, Junji Hiraga, Michihiko Narita, Yoshimasa Tanikawa, Tomoyuki Tsuzuki

“…Six years earlier, he was diagnosed with multiple myeloma (MM) and was treated with several chemotherapies. He was also diagnosed with gastric cancer with liver metastasis and primary lung cancer by upper gastrointestinal endoscopy and computed tomography (CT). …”
Get full text

Case report: Musculoskeletal metastastic inflammatory myofibroblastic tumor (IMT) treated by sequential ALK-TKI with longterm response by Thomas Cochin, Sabine Noal, Dinu Stefan, Damien Bodet, Jérémie Rouger, Marine Dorbeau, Zoé Neviere

“…The treatment of this type of tumor includes systemic therapies such as chemotherapies or anti-inflammatories; in recent years, targeted anti-ALK therapies have emerged and became the standard of care in ALK rearranged patients. …”
Get full text

Resolved Hepatitis B: Achieved or Imaginary Wellbeing? by S. N. Batskikh

“…Occult HBV infection in PHB individuals can reactivate at background immunosuppressive or chemotherapies. PHB with chronic liver diseases of various aetiology significantly rises the risk of cirrhosis and hepatic cancer. …”
Get full text

Renal Cancer Stem Cells: Characterization and Targeted Therapies by Anna Julie Peired, Alessandro Sisti, Paola Romagnani

“…As CSCs are involved in the resistance mechanisms to radio- and chemotherapies, several new strategies have been proposed to directly target CSCs in RCC. …”
Get full text

The Key to Unlocking the Chemotherapeutic Potential of PPARγ Ligands: Having the Right Combination by Graham Skelhorne-Gross, Christopher J. B. Nicol

“…Here we have compiled an extensive review, consolidating the existing literature, which overwhelmingly supports a beneficial effect of treating with PPARγ ligands in combination with existing chemotherapies versus their monotherapy in cancer. There are many examples in which combination therapy resulted in synergistic/additive effects on apoptosis, differentiation, and the ability to reduce cell growth and tumour burden. …”
Get full text

An Unusual Presentation of Desmoplastic Small Round Cell Tumour of the Abdomen: Morphological, Immunohistochemical, Ultrastructural, and Molecular Studies by Preethika Angunawela, Alhossain A. Khalafallah, Karen Wolfswinkel, David Seaton, Terry Brain

“…The patient succumbed 34 months from disease presentation after multiple chemotherapies and thereafter radiotherapy. In summary, our case exemplifies that it is crucial to combine clinical, histological, and molecular aspects in diagnosing DSRCT especially when characteristic dot positivity with desmin is weak along with deficient marking of WT1 and CD99 by immunohistochemistry. …”
Get full text